What the numbers actually mean
A standard lipid panel reports four numbers:
- Total cholesterol — the sum of cholesterol carried in all the lipoprotein classes. Less informative than the components.
- LDL cholesterol — the cholesterol content of low-density lipoprotein particles. The traditional treatment target.
- HDL cholesterol — the cholesterol in high-density lipoprotein particles. Generally protective at higher levels, though raising HDL pharmacologically has not consistently improved outcomes.
- Triglycerides — the fat content of VLDL and chylomicron particles. Elevated levels independently drive risk and are particularly informative when combined with apoB.
Most modern guidelines treat to LDL targets that depend on overall risk:
- Primary prevention, lower risk: LDL roughly < 100 mg/dL
- Primary prevention, higher risk (family history, multiple risk factors, calcified plaque on imaging): LDL < 70 mg/dL
- Secondary prevention (prior heart attack, stroke, established coronary disease): LDL < 55 mg/dL, sometimes < 40
The right target for you depends on the full picture, not the LDL number alone — which is where the more comprehensive workup matters.
What standard testing misses
The basic lipid panel is a reasonable screening test. It is not enough for the patients in whom the answer most matters. The tests that fill in the picture:
Apolipoprotein B (apoB)
A direct count of the atherogenic particles in your blood. Every LDL, VLDL, IDL, Lp(a), and remnant particle carries exactly one apoB molecule, so apoB is the most accurate available measure of total atherogenic particle burden. In about a third of patients, apoB and LDL tell meaningfully different stories — and apoB is the one that better predicts cardiovascular events. The target is roughly < 90 mg/dL for primary prevention, < 80 for elevated risk, and < 65–70 for secondary prevention.
Lipoprotein(a) — Lp(a)
A genetically determined, independent driver of heart attack and aortic valve disease. About 20% of the population has an elevated Lp(a) and most have never had it measured. One-time blood test; the result is essentially stable for life. Elevated Lp(a) does not respond meaningfully to standard lipid therapies (new Lp(a)-lowering agents are in late-stage trials), so the practical use of the result is to intensify treatment of every other lipid lever and to inform family screening.
High-sensitivity CRP (hs-CRP)
A measure of systemic inflammation. Persistently elevated hs-CRP independently increases cardiovascular risk and is a target of its own — and the newer anti-inflammatory therapies (colchicine for cardiovascular indications) target exactly this axis in selected patients.
Coronary artery calcium (CAC) score
A low-radiation CT scan that directly visualizes plaque calcification in the coronary arteries. A zero score in your 50s or later is a strong reassurance signal. A non-zero score restratifies cardiovascular risk in a way no blood test can, and often shifts treatment intensity. Particularly useful when the risk picture is intermediate and the standard panel does not obviously point to a clear treatment intensity.
Genetic testing for familial hypercholesterolemia (FH)
Considered when LDL is markedly elevated from a young age, when first-degree relatives have premature coronary disease, or when physical signs (tendon xanthomas, corneal arcus before age 45) point that way. A confirmed FH diagnosis changes both the treatment intensity and the screening recommendations for first-degree relatives, who carry a 50% chance of also having the condition.
How treatment is decided
The decision is not "should I take a statin" — it is "what combination of lifestyle and pharmacologic levers gets you to target." The available tools, used in order of typical sequence:
Lifestyle
Worth doing for everyone, and meaningful for many. A Mediterranean-pattern or DASH-pattern diet has the strongest evidence base; saturated-fat reduction lowers LDL by ~5–15% depending on baseline; sustained weight loss in overweight patients improves the whole lipid panel. Exercise raises HDL and lowers triglycerides. Lifestyle alone often does not get high-risk patients to target, but it amplifies the effect of medication when added.
Statins
Still the foundation when medication is indicated. The right approach is the right statin and dose to reach your target — not "any low-dose statin started years ago and never titrated." Modern high-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) lower LDL by 50%+ and have strong outcomes data across multiple populations.
Ezetimibe
Inexpensive, well-tolerated oral agent that reduces dietary cholesterol absorption and lowers LDL an additional ~15–25% when added to a statin. The IMPROVE-IT trial confirmed cardiovascular benefit. Underused in routine practice; often the right first add-on when statin alone falls short of target.
PCSK9 inhibitors and inclisiran
Injectable monoclonal antibodies (evolocumab, alirocumab) and siRNA (inclisiran) that further lower LDL and apoB by 50–60% on top of statin therapy. Strong outcomes data. Coverage has expanded substantially since their launch; we handle prior authorization.
Bempedoic acid
Oral, statin-independent. Useful in statin-intolerant patients and as an additional lever for patients who cannot reach target on statin alone. Outcomes data positive for high-risk patients.
Icosapent ethyl
Evidence-based add-on for high-risk patients with persistently elevated triglycerides on statin therapy. The REDUCE-IT trial showed clear cardiovascular benefit in that population.
How virtual cardiology handles high cholesterol
Lipid management is one of the cleanest fits for virtual care. The workflow is essentially a series of structured conversations around lab results and medication adjustments, both of which work well by video:
- First visit by video. History, family history, prior labs, current medications, goals. Order the right level of lipid panel (basic, advanced with apoB and Lp(a), or genetic if indicated).
- Labs drawn near you. Quest, LabCorp, or a local lab; results return electronically.
- Follow-up visit by video to interpret results and build the plan. Set the target, pick the regimen, write the prescription.
- Titration visits over a few months. Repeat labs at 8–12 weeks after each change to confirm response. Most patients reach target in two to four cycles.
- Ongoing maintenance. Annual labs and one virtual visit per year for stable patients.
The bottom line
Lipid management is among the highest-leverage things in adult medicine. Done with the full modern toolkit and tuned to apoB rather than just LDL, the right plan can reduce cardiovascular event risk dramatically — and most of the work runs cleanly through a virtual cardiology relationship.
If you are interested in the longevity-oriented approach to lipid management — advanced testing, Lp(a) status, CAC scoring, polygenic risk — our Advanced Lipid Management program is built for that. The Longevity Cardiology program places lipid management in the broader frame of evidence-based cardiovascular risk reduction.